Concepedia

Publication | Closed Access

<i>IDH1</i> or <i>IDH2</i> mutations predict longer survival and response to temozolomide in low-grade gliomas

DOI

528

Citations

30

References

2010

Year

Caroline Houillier, X. Wang, Gentian Kaloshi, Karima Mokhtari, Rémy Guillevin, Julien Laffaire, S. Paris, Blandine Boisselier, Ahmed Idbaïh, Florence Laigle–Donadey,
Neurology

Abstract

IDH mutation appears to be a significant marker of positive prognosis and chemosensitivity in low-grade gliomas, independently of 1p-19q codeletion, whereas its impact on the course of untreated tumors seems to be limited.

References

YearCitations

Page 1